To receive Noxxon’s real time information, please send a request to This email address is being protected from spambots. You need JavaScript enabled to view it.


Usage of Cookies
We use cookies to better understand your use of this website. This enables us to improve your future experience on our website. Detailed information about our use of cookies can be found in our privacy policy. If you continue to use this website we will assume that you agree with the usage of cookies. You can prevent cookies from being installed or delete them from your computer. How this works, is explained in our privacy policy. Imprint

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. NOXXON disavows any obligation to update the information contained in such press releases after the date of their issuance.

Filter: NOX-A12 (olaptesed)NOX-E36 (emapticap) | all


2019, May 03
8:00 p.m.
NOXXON announces change within supervisory board

2019, April 12
7:00 p.m.
NOXXON Pharma N.V. reports 2018 financial results

2019, April 01
7:00 p.m.
NOXXON presents updated results from Phase 1/2 NOX-A12 / Keytruda combination trial at AACR 2019

2019, February 28
7:00 p.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at the 2019 AACR Annual Meeting

2019, February 27
6:00 p.m.
NOXXON files application for phase 1/2 clinical trial combining NOX-A12 & radiotherapy for the treatment of brain cancer

2019, February 18
8:00 a.m.
NOXXON publishes a shareholder letter

2019, February 01
8:00 a.m.
New data published supporting monotherapy activity of CCL2 inhibitor NOX-E36 in an additional solid tumor type: liver cancer

2019, January 14
6:00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2019, January 04
8:00 a.m.
Results of NOXXON's extra-ordinary general meeting of shareholders

2018, December 20
8:00 a.m.
NOXXON announces participation in the East/West CEO Forum in San Francisco, in January 2019

2018, December 14
12:30 p.m.
NOXXON announces key findings that NOX-A12 plus Keytruda induces an immune response and results in clinical benefit for patients

2018, December 13
8:00 p.m.
NOXXON announces trading halt on Euronext Growth Paris ahead of trial data publication at the ESMO Immuno-Oncology Congress

2018, December 10
8:00 a.m.
NOXXON to present latest clinical data from NOX-A12 / Keytruda combination trial at ESMO immuno-oncology congress on December 13-16, 2018

2018, December 03
0:01 a.m.
NOXXON announces convocation of an extra-ordinary general meeting of shareholders

2018, November 21
8:00 a.m.
NOXXON to launch NOX-A12 with radiotherapy clinical trial in patients with brain cancer

2018, November 16
8:00 a.m.
NOXXON announces EUR 6.2 million equity capital raise including US$ 5 million from US family office - Acuitas Capital, LLC

2018, October 26
8:00 a.m.
NOXXON to present top-line efficacy data from NOX-A12 / Keytruda combination trial in December as planned at ESMO Immuno-Oncology Conference

2018, October 23
6:00 p.m.
NOXXON to attend European investor and partnering conferences in November 2018

2018, October 16
8:00 a.m.
NOXXON to attend the ESMO 2018 congress in Munich

2018, October 11
8:00 a.m.
NOXXON publishes interim 2018 results

2018, October 02
6:00 p.m.
NOXXON presents top-line data from NOX-A12 monotherapy part of ongoing metastatic colorectal and pancreatic cancer trial

2018, September 19
6:00 p.m.
NOXXON announces listing of convertible bonds and additional investment

2018, September 19
8:00 a.m.
NOXXON to present clinical trial data at Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 'Translating Science into Survival'

2018, September 03
8:00 a.m.
NOXXON announces completion of patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, August 14
8:00 a.m.
NOXXON raises additional funds via ODIRNANE bonds and extends timing to cancel investor's unilateral right to invest

2018, August 08
6:00 p.m.
NOXXON to host Key Opinion Leader event on novel treatment approaches for glioblastoma on September 4th, 2018

2018, August 01
8:00 a.m.
NOXXON announces that it has secured additional financing

2018, July 16
6:00 p.m.
NOXXON announces amendment to loan agreements

2018, July 13
6:00 p.m.
Half-yearly report on the liquidity contract with invest securities

2018, July 03
8:00 a.m.
NOXXON issues tranche of ODIRNANE bonds

2018, June 28
8:00 p.m.
NOXXON provides update on patient recruitment in ongoing NOX-A12 pancreatic and colorectal cancer trial

2018, June 22
8:00 a.m.
Results of NOXXON annual general shareholders meeting

2018, June 15
8:00 a.m.
NOXXON announces that it has secured additional financing

2018, June 06
6:00 p.m.
NOXXON issues seventh tranche of ODIRNANE bonds

2018, May 29
8:00 a.m.
NOXXON provides clinical update prior to American Society of Clinical Oncology (ASCO) annual conference

2018, May 18
6:00 p.m.
NOXXON announces convocation of the annual general meeting of shareholders

2018, May 15
6:00 p.m.
NOXXON to present clinical trial update at BioEquity Europe

2018, April 30
9:00 p.m.
NOXXON PHARMA N.V. reports 2017 financial results

2018, April 26
8:00 a.m.
NOXXON publishes results of extraordinary shareholders meeting

2018, April 10
8:00 a.m.
NOXXON announces initiation of analyst coverage by Aurgalys

2018, March 22
9:00 p.m.
NOXXON announces convocation of an extra-ordinary general meeting of shareholders

2018, March 13
8:00 a.m.
NOXXON renegotiates ODIRNANE BSA financing agreement to remove unilateral option for investor to subscribe for tranches and to cancel existing warrents

2018, January 31
6.00 p.m.
Half-yearly report on the liquidity contract with Invest Securities

2018, January 23
8:00 a.m.
NOXXON issues fourth tranche of ODIRNANE bonds

2017, November 22NOXXON announces its participation in three European investor conferences in November and December 2017

2017, November 21NOXXON issues third tranche of ODIRNANE bonds

2017, October 30NOXXON releases interim 2017 results

2017, October 11NOXXON Pharma réaffirme son éligibilité au PEA-PME pour 2017/2018 (French only)

2017, October 03NOXXON Publishes Preclinical Proof-Of-Concept Data for Lead Compound NOX-A12 in Combination with Checkpoint Inhibitors

2017, September 29NOXXON Supervisory Board elects experienced US and EU biotech veteran Don deBethizy chairman

2017, September 28NOXXON provides update on ongoing phase 1/2 clinical trial with lead program NOX-A12

2017, September 26NOXXON announces its participation in two french investor conferences in October 2017

2017, September 19NOXXON issues second tranche of ODIRNANE bonds

2017, August 25Half-yearly report on the liquidity contract with Invest Securities

2017, July 18NOXXON issues first tranche of ODIRNANE bonds

2017, July 11NOXXON Pharma announces prospectus publication and share transfer to the public offering compartment of the EuroNext Growth market

2017, July 04NOXXON announces first patients treated in phase I/II clinical trial of NOX-A12 combined with Keytruda in metastatic pancreatic and colorectal cancer

2017, June 29Results of NOXXON Annual General Meeting

2017, June 07NOXXON publishes Annual General Meeting Documents

2017, May 26NOXXON announces record date and date of annual general meeting

2017, May 16NOXXON Pharma announces collaboration with National Center for Tumor Diseases in Heidelberg for NOX-A12/Keytruda phase 1/2 combination trial


2017, April 30NOXXON Pharma N.V. reports 2016 financial results and announces advanced discussions regarding a convertible bond financing

2017, February 10NOXXON Pharma announces experienced industry cancer clinician Dr. Jarl Ulf Jungnelius to serve as NOXXON CMO

2017, January 06Half-yearly report on the liquidity contract with INVEST securities

2017, January 04NOXXON PHARMA licenses and assigns preclinical Spiegelmer programs to APTARION

2016, December 15NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer

2016, December 05NOXXON Pharma announces new preclinical data showing synergy of lead compound NOX-A12 with natural killer (NK) Cell mediated therapies

2016, October 31NOXXON releases its interim 2016 results

2016, October 24NOXXON Pharma announces the implementation of a liquidity contract with invest securities

2016, October 10NOXXON Pharma demonstrates synergies between NOX-A12 and therapies working through T cells or NK cells

2016, September 28NOXXON Pharma NV lists its shares on Alternext Paris

2016, January 20NOXXON Pharma hosts key opinion leader symposium

2015, July 14NOXXON appoints Aram Mangasarian as CEO

2015, May 29First Data from NOXXONs NOX-H94 (Lexaptepid Pegol) Clinical Trial in ESA-Hyporesponsive Dialysis Patients Reported at ERA-EDTA Conference

2015, April 23Nature Communications Publications on the First X-ray Crystal Structures of Spiegelmers Bound to Protein Targets

2014, December 10New Addition to NOXXON Supervisory Board Brings Significant US Public Market Expertise

2014, December 05Phase IIa Results for Spiegelmer Olaptesed Pegol (NOX-A12) in MM and CLL at 2014 American Society of Hematology (ASH) Conference

2014, September 26Cell Reports Publication on the Mechanism of Action of NOXXONs Anti-SDF-1 Spiegelmer Olaptesed Pegol (NOX-A12) in Preclinical Multiple Myeloma Models

2014, September 23NOXXON Spiegelmer receives FDA Orphan Drug Designation for Glioblastoma Treatment

2014, September 18NOXXON Pharma Expands Management Team by Appointing Don Munoz as Chief Financial Officer

2014, September 04Two Presentations at International Conferences of Preclinical Data on NOXXON's anti-C5a Spiegelmer, a Potential Drug in Pneumococcal Pneumonia-Induced Sepsis

2014, July 31NOXXON Initiates Phase IIa Study of Anti-Hepcidin Spiegelmer Lexaptepid Pegol (NOX-H94) in Dialysis Patients with EPO-hyporesponsive Anemia

2014, June 13NOXXON presents Updates on Phase II Studies with Olaptesed Pegol (NOX-A12) in CLL and MM and Lexaptepid Pegol (NOX H94) in Anemic Cancer Patients

2014, June 02NOXXONs Emapticap Pegol Study Selected for Late Breaking Clinical Trials Symposium during ERA-EDTA Conference

2014, April 08Anti-Hepcidin Spiegelmer Lexaptepid Pegol Increases Hemoglobin in Subset of Anemic Patients in Pilot Phase IIa Study

2014, April 04NOXXON presents Positive Results from Emapticap Pegol Phase IIa Diabetic Nephropathy Study

2013, December 09NOXXON presenting at ASH 2013

2013, July 24NOXXON Pharma Completes Patient Recruitment for Phase IIa Study in Diabetic Nephropathy

2012, December 04NOXXON Initiates Phase IIa of Anti-Hepcidin Spiegelmer NOX-H94

2012, September 26NOXXON Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 in Second Oncology Indication: Multiple Myeloma

2012, July 11NOXXON Initiates Phase IIa of anti-CXCL12/SDF-1 Spiegelmer NOX-A12 for Treatment of Chronic Lymphocytic Leukemia

2012, June 19NOXXON Initiates Phase IIa of Spiegelmer NOX-E36 for Treatment of Diabetic Nephropathy

2012, April 4NOXXONs NOX-A12 Delays Glioblastoma Recurrence in Preclinical Model

2012, January 6NOXXON to Present at 30th Annual J.P. Morgan Healthcare Conference

2011, December 12NOXXONs SDF-1 inhibitor NOX-A12 completes Phase I

2011, September 06NOXXON initiates Phase I of NOX-H94 for Anemia of Chronic Disease

2011, February 03NOXXON Expands Management Team

2010, October 12NOXXON Confirms Total Capital Raise of €35m

2010, September 22NOXXON initiates multiple dose phase I clinical trial of SDF-1 inhibitor NOX-A12

2010, July 7NOXXON to initiate phase Ib clinical trial of MCP-1 inhibitor NOX-E36

2010, June 28NOXXON Pharma AG announces management changes

2010, May 27NOXXON Pharma AG raises €33 million in Series D Round

2010, May 18NOXXON Pharma AG appoints Dr. Aram Mangasarian as Chief Business Officer

2010, May 3NOXXON Announces the Completion of the First-in-Human Clinical Trial with Spiegelmer NOX-A 12

2009, December 3NOXXON Pharma AG Achieves Milestone in Partnership with Eli Lilly and Company

2009, November 2NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer NOX-A12

2009, October 12NOXXON announces excellent preliminary phase I trial results for Spiegelmer NOX-E36

2009, September 3NOXXON Is Awarded Research and Development Grant for First-in-Human Clinical Trial with Spiegelmer NOX-A12

2009, June 8NOXXON Announces Initiation of First Clinical Trial with a Spiegelmer

2008, July 8NOXXON Pharma announces appointment of Lawrence E. Posner to its Board of Directors

2008, June 11NOXXON Pharma AG Announces Licensing and Discovery Collaboration with Eli Lilly ...

2008, April 7NOXXON Receives Research Grant from the Federal Ministry of Education and Research

2008, January 7NOXXON Pharma AG appoints Dr. Frank Morich as CEO

2007, November 9NOXXON announces alliance with Roche

2007, June 8NOXXON Pharma announces appointment of Dr. Walter Wenninger as Chairman of the Board

2007, May 3NOXXON Pharma closes Series C Round at Euro 37 million

2007, February 9NOXXON Pharma AG to present at Bio CEO & Investor Conference 2007 in New York

2006, November 3NOXXON Pharma AG to present at Bio-Europe in Duesseldorf, Germany

2006, November 3NOXXON Pharma AG to present at Rodman & Renshaw 8th Annual Healthcare Conference

2006, October 4NOXXON Pharma AG to present at Sachs Associates 6th Annual Biotech in Europe...

2006, May 12NOXXON Pharma AG to present at the Rodman & Renshaw 3rd Annual Global Healthcare...

2006, May 10Change of management at NOXXON Pharma AG

2006, March 23NOXXON Pharma AG announces global strategic alliance with Pfizer. NOX-B11...

2006, March 15NOXXON Pharma AG announces publication of positive animal data with its vasopressin

2006, March 13NOXXON Pharma AG to present at Sachs Associates’ 5th Annual North America Forum...

2006, February 13NOXXON Pharma AG to present at Bio CEO & Investor Conference 2006 in New York